Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Dexamethasone (Dex) is a synthetic corticosteroid hormone derived from the steroid chemical group and is applicable in treating several pathological conditions like inflammation, autoimmune disease, and malignancies. Recent investigations on the mechanism of action of Dex and its possible interactions with other cellular regulatory networks may help explain the inconsistent effects of Dex in cancer treatment. Finetuning regulation of essential post-transcriptional regulators such as microRNA (miRNAs) has indispensable impacts on modulating fundamental cellular processes, including gene expression, cell proliferation, cell cycling, and apoptosis. Dex appears to act as a double-edged sword on cancer cell progression and metastasis through regulating miRNA networks. As a proof of concept, recent investigations have proved Dex to be effective in treatment of cancer either individually or in combination with other therapeutical compounds, while several evidences have point to the controversial effects of Dex in the promotion of cancer cell survival, drug-resistance, and metastasis. In addition, it has been proven that other non-coding RNAs (ncRNAs) can also be directly or indirectly affected by Dex. In this review, we aimed to investigate the controversial effect of Dex on the cancer-related miRNAs.

Loading

Article metrics loading...

/content/journals/cmm/10.2174/1566524020666200925155614
2021-06-01
2025-09-29
Loading full text...

Full text loading...

/content/journals/cmm/10.2174/1566524020666200925155614
Loading

  • Article Type:
    Review Article
Keyword(s): apoptosis; cancer; Dexamethasone; drug resistance; invasion; miRNA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test